… the difficulty posed by erlotinib resistance. Delivery systems … bioavailability and solubility
of erlotinib, thereby potentially … the precise administration of erlotinib to particular malignant …

… The four experimental groups established for comparative studies were as follows: Group
I rats received a 10 mg/kg dose of pure ERL via oral delivery, Group II rats received the same …

… and erlotinib, we searched databases including clinical trial randomized studies and reviews
… In conclusion, the study shows that the bevacizumab–erlotinib combination significantly …

… study, we aimed to unveil key intracellular molecules and adjuvant reagents to overcome
erlotinib … In conclusion, our data support the application of quercetin in anti-erlotinib-resistant …

… However, there is no report on application of aptamer-tagged Erlotinib loaded chitosan
nanoparticles. Hence the present study was to develop the DDS using the dual stimuli-…

… erlotinib formation: We studied … Erlotinib and resveratrol concentration in our study were
chosen based on previous in vitro experiments that studied the effect of resveratrol on erlotinib …

… erlotinib among patients with HNSCC. For the first time, this study shows that an increased
erlotinib … 150 mg in non-smokers, with increased study-specific defined tumor response. The …

… An in vitro drug release study was performed in order to determine the release behavior of
the Erlotinib HCl from nanoparticles. For this study, freeze-dried nanoparticles of Erlotinib HCl …

… Erlotinib (ERL) is a tyrosine kinase inhibitor associated with the epidermal growth factor
receptor (EGFR) containing susceptible functional groups such as quinazoline and amine ketone…

… studies between the latest generation of drugs. Consequently, ambiguous areas exist due to
the lack of comparative studies … Additionally, the BEVERLY study aimed to study the erlotinib…